Latest Hyperphosphatemia News
Patients on hemodialysis who achieved serum phosphate levels below 4.5 mg/dL experienced a decrease in intact fibroblast growth factor 23.
In a study, hemodialysis patients who used phosphate binders had up to a 44% decreased risk of dying from infection than those who did not use the drugs.
Clinicians were able to reduce doses of erythropoiesis-stimulating agents and intravenous iron.
Patients with serum phosphate levels of 4.9 mg/dL or higher upon admission had the worst survival.
Midweek serum phosphate levels can differ from levels measured after a weekend.
Median intact FGF-23 significantly fell by 64% over 1 year of treatment with sucroferic oxyhydroxide or sevelamer.
Meta-analysis shows that nicotinic acid could be a good alternative or add on to traditional phosphate binders, but it is associated with a high rate of adverse events.
In a meta-analysis, hemodialysis patients using lanthanum carbonate to lower phosphorus levels had a 55% decreased risk of death compared with those taking other binders.
A serum phosphate control target of 4.5 mg/dL or below in hemodialysis patients was accompanied by a decline in fibroblast growth factor 23.
Mean 25-hydroxyvitamin D levels did not differ significantly among groups receiving phosphate binders or dietary therapy.
In a study, intact parathyroid hormone levels fell by nearly 10% over 6 months in hemodialysis patients who received intensive treatment for hyperphosphatemia.
Excess calcium following a meal may be deposited in soft tissue and blood vessels, researchers hypothesize.
Sucroferric oxyhydroxide and sevelemer are similarly effective in lower phosphorus levels in dialysis patients, but the former is associated with less toxicity and lower pill burden.
In addition, average phosphate binder pill burden decreased by more than half.
Panel focuses on diagnosing and testing of CKD-MBD and treatment of the CKD-MBD that emphasizes decreasing phosphate, maintaining calcium, and addressing elevated PTH in adults with CKD stage G3a to G5.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer